drugset / Trial / NCT07021898
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Non-randomizedSequentialOpen-labelTreatment
Summary
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.
Timeline
- Start
- 2025-08-06
- Primary completion
- 2028-08
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ERAS-4001 | Unknown | — | Oral |
| Background | Panitumumab | Monoclonal antibody | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |